FIGURE 3.

αPD-L1 treatment increases K⁺ channel activity in HNSCC patients. (A) KCa3.1 and (B) Kv1.3 conductance values (G) measured with and without the αPD-L1 antibody, atezolizumab (1 and 10 μg/ml for 6 h) in activated CD8⁺ PBTs of HNSCC patients. (C) KCa3.1 and (D) Kv1.3 G measured in presence of PD-L1 and αPD-1 antibody pembrolizumab in activated CD8⁺ PBTs of HDs. Activated cells were treated with plate-bound PD-L1 (PD-L1-Fc 10 μg/ml) +/- αPD-1 (untreated cells were used as a control) and activated for 72 h using PMA/Ionomycin. αPD-1 was added to treatment group for 6 h. Data in the lower and upper bound of the box represent 25^th and 75^th percentiles respectively. Median values are shown as horizontal lines. The lower and upper error bars represents 10^th and 90^th percentile respectively, n = 8–23 cells from 3 HNSCC patients, n = 30 cells from 6 HDs (control and PD-L1) and n = 15 cells from 3 HDs (PD-L1 + αPD-1). Five cells were recorded for each individual donor. Data in (A,C,D) were analyzed by ANOVA on ranks test (p < 0.001) followed by Dunn’s post hoc analysis. Data in (B) were analyzed by One way ANOVA (p < 0.001) followed by Holm-Sidak test.